Navigation Links
Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
Date:9/27/2010

SAN DIEGO, Sept. 27 /PRNewswire-FirstCall/ -- Amira Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for AM152, a novel LPA1 antagonist.  If accepted, the IND will enable Amira to begin Phase 1 safety studies with the compound in healthy subjects.

"We believe the pre-clinical data obtained to date for AM152 demonstrate characteristics which warrant further studies in humans to determine its potential utility in various fibrotic diseases," said Isabelle DeArmond, Vice President, Clinical Development. "The safety and pharmacokinetic data obtained from Phase 1 studies are an important first step in the clinical investigation of this program."

Added Bob Baltera, Chief Executive Officer, "We are extremely excited to reach this point with our LPA1 program. There have recently been numerous papers published describing the novel biology of the LPA1 receptor and how it relates to abnormal fibrotic processes.  We have worked hard to develop this program and look forward to learning more about this potential therapeutic candidate in a clinical setting."

While there are no LPA1 selective antagonists approved for therapeutic use, there is a strong scientific rationale for this target to be a novel treatment in various fibrotic diseases, including scleroderma and idiopathic pulmonary fibrosis.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.  Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase-activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®. The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future.  For more information, visit www.amirapharm.com.


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
2. Visage Imaging Releases Amira 5.3
3. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
4. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
5. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
6. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
7. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
8. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
9. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
10. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
11. Lotus Pharmaceuticals Announces Two Senior Management Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... SAN FRANCISCO , May 23, 2016 ... expected to reach USD 5.0 billion by 2022, according ... The increasing generation of medical waste coupled with the ... healthcare industry is expected to drive the demand for ... with these devices as compared to that of the ...
(Date:5/20/2016)... ReportsnReports.com adds Global Titrator ... of its online business intelligence library. This is ... state of the Titrator industry. The report provides ... classifications, Specifications, applications and industry chain structure. Report ... Material Suppliers, Equipment Suppliers, Manufacturing Cost Structure, Price ...
(Date:5/20/2016)... , May 20, 2016 According to ... is the increasing demand for affordable healthcare solutions as since ... on the rise. In countries like the US, the healthcare ... the US, the consumer price index inflation rate stood at ... rate moved up to 3.62% during the same time period. ...
Breaking Medicine Technology:
(Date:5/25/2016)... IN (PRWEB) , ... May 25, 2016 , ... ... group health insurance, has seen a significant spike in their clients' employee participation ... their annual biometric health screening by implementing a high-deductible health plan with outcome-based ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... has announced that it will join America's leading engineers at the American Society ... at the Georgia World Congress Center. , Engineers, speakers and exhibitors from ...
(Date:5/24/2016)... LA (PRWEB) , ... May 24, 2016 , ... Sterling ... will feature a unique and patented refillable hanging wipe dispenser. The campaign kick-off video ... 2016 and will end June 25, 2016. The goal is to raise $1,000 per ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... of its services to provide one resource, from start to finish, for Life ... Life Safety Statement of Condition surveys requested by the Joint Commission, and fire ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... pleased to welcome new Partner Firm Austin & Co., Inc. Headquartered in ... insurance, employee benefits, HR consulting, benefits technology, and beyond. As an employee-owned ...
Breaking Medicine News(10 mins):